In this manuscript, we have shown that by specifically targeting the mutation site R176Q on Ryr2 in a mouse model of CPVT, we could prevent arrhythmogenesis without significant long-term effects on baseline cardiac function. This evidence concerns the gene RYR2 and catecholaminergic polymorphic ventricular tachycardia.